With AbbVie-Allergan decision, Simons draws the line, blasts Dems
Perhaps more than in any other case since Joe Simons became chairman of the Federal Trade Commission, the 3-2 decision approving drugmaker AbbVie’s $63 billion buyout of rival Allergan reveals his...To view the full article, register now.
Already a subscriber? Click here to view full article